Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer (NCT02226276)
This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to other places in the body. Copper Cu 64-DOTA-trastuzumab is a chemotherapy drug (trastuzumab (Herceptin®;Genentech, Inc.)) attached to a radioactive substance. Diagnostic procedures using PET may allow scanners to take pictures of where the drug travels in the body and may help doctors identify which patients may benefit from treatment with ado-trastuzumab emtansine.
This trial is sponsored by City of Hope Medical Center 
- Bone Metastases
- HER2-positive Breast Cancer
- Liver Metastases
- Lung Metastases
- Recurrent Breast Cancer
- Soft Tissue Metastases
- Stage IV Breast Cancer
- Drugs used in this trial
- Radiation: fludeoxyglucose F 18
- Procedure: positron emission tomography
- Procedure: computed tomography
- Radiation: copper Cu 64-DOTA-trastuzumab
- Other: laboratory biomarker analysis
- Estimated Enrollment: 10
- Start: January 2015
- Estimated Completion: December 2016
- Last verified: May 2015
Last Editorial review: July 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.